Palliative Radiotherapy for Diffuse Large B-Cell Lymphoma

Abstract Recent improvements in chemmoimmmunotherapies, targeted agents, hematopoietic stem cell transplants, and cellular therapies have revolutionized treatment paradigms for patients with diffuse large B-cell lypmhoma (DLBCL). Even in the relapsed or refractory setting, contemporary treatment options are delivered with curative intent and can lead to lasting remissions. While such therapies have improved overall outcomes, they have increasingly led to a wide variety of presentations of recurrent tumors in need of palliation. Here, we review the use of radiotherapy (RT) in the palliation of DLBCL. We draw particular attention to the evolving role for hypofractionated RT and low-dose radiotherapy (LDRT) for DLBCL. We review the available literature on these topics and focus on commonly encountered clinical scenarios.